Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Improving response to immune checkpoint blockade in cSCC

Paolo Bossi • 5 Jun 2022
ASCO 2022
Skin Cancer

Paolo Bossi, MD, University of Brescia, Brescia, Italy, reflects on ongoing treatment approaches currently under investigation in patients with cutaneous squamous cell carcinoma, including the role of combined systemic immunotherapy and intra-tumoral injection of a modified herpes-simplex virus with the intention to improve response to immune checkpoint blockade. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Paolo Bossi

1:37
The future role of immunotherapy in head and neck cancer
Paolo Bossi • 27 Mar 2023
2:09
HPV status, artificial intelligence, and IO in head and neck cancer
Paolo Bossi • 27 Mar 2023
4:29
The role of quality of life in the management of head and neck cancer
Paolo Bossi • 27 Mar 2023
1:25
Reducing oral mucositis in patients treated with CRT using avasopasem manganese
Paolo Bossi • 5 Jun 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals